IMMUNOBIOTICS, INC. Financials

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...
Click here to read the whole Article (external link)

IMMUNOBIOTICS, INC. Files SEC form 10-Q, Quarterly Report

Item 2. Management's Discussion and Analysis of Plan of Operations This discussion and analysis should be read in conjunction with the accompanying Financial Statements and related notes. Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of any contingent liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. On an on-going basis we review our estimates and assumptions. Our estimates are based on our historical experience and other assumptions that we believe to be reasonable under the circumstances. Actual results are likely to differ from those estimates under different assumptions or conditions, but we do not believe such differences will materially affect our financial position or results of operations. Our critical accounting policies, the policies we believe are most important to the presentation of our financial statements and require the most difficult, subjective and complex judgments, are outlined below in ''Critical Accounting Policies,'' and have not changed significantly. FORWARD-LOOKING STATEMENTS Certain statements made in this report may constitute "forward-looking statements on our current expectations and projections about future events". These forward-looking statements involve known or unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the Registrant to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases you ...
Click here to read the whole Article (external link)

IMMUNOBIOTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. or By

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. (a) N/A (b)(c) On May 14, 2009, ImmunoBiotics, Inc. announced the appointment of Daniel Smith, age 64, to the position of President and Chief Executive Officer. Mr. Lahey had been our President and Chief Executive Officer, a position he held since July 20, 2007. Mr. Lahey will remain as our Chairman of the Board of Directors. Mr. Smith has served as a consultant to the Company since November 2007. Mr. Smith also is and since 1998 has been the Chief Executive Officer and President of S.F.T. International, a company that he founded which is focused in the area of health and wellness. From 1998 until 2008, Mr. Smith also served as the Chief Executive Officer and President of USA Pharmaceuticals, a company he founded to introduce health products made in America into the China market. Also, on May 14, 2009, ImmunoBiotics, Inc. announced the appointment of Gerald Lindberg, age 60, to the position of Chief Financial Officer. Mr. Vithal Rajdhyaksha had been our Chief Financial Officer, a position he held since July 20, 2007. Mr. Rajdhyaksha will continue to be our Company's Secretary. Mr. Lindberg has served as a consultant to the Company since January 2009. He also serves as a consultant to several companies including: Telegistics International, a provider of investment banking services to various companies where he has served as a consultant since 1998; Sycamore Films, an Urban film production company where he has served as a consultant since 2008; Hammerly Associates (formerly Raptive Software), a database software and user interface company where he has served as a consultant since 2008; MindFX Science, a sports and energy drink company where he has served as a consultant since 2007; COO DXM Corporation, a software company where he has served as a consultant since 2005. From March 2003 until March 2005, Mr. Lindberg was a consultant to the Vice President of Opera...
Click here to read the whole Article (external link)

IMMUNOBIOTICS INC Files SEC form 10-Q, Quarterly Report

Item 2. Management's Discussion and Analysis of Plan of Operations This discussion and analysis should be read in conjunction with the accompanying Financial Statements and related notes. Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of any contingent liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. On an on-going basis we review our estimates and assumptions. Our estimates are based on our historical experience and other assumptions that we believe to be reasonable under the circumstances. Actual results are likely to differ from those estimates under different assumptions or conditions, but we do not believe such differences will materially affect our financial position or results of operations. Our critical accounting policies, the policies we believe are most important to the presentation of our financial statements and require the most difficult, subjective and complex judgments, are outlined below in ''Critical Accounting Policies,'' and have not changed significantly. FORWARD-LOOKING STATEMENTS Certain statements made in this report may constitute "forward-looking statements on our current expectations and projections about future events". These forward-looking statements involve known or unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the Registrant to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases you ...
Click here to read the whole Article (external link)

IMMUNOBIOTICS INC Files SEC form 10-K, Annual Report

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONS The following discussion of our financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements included elsewhere in this prospectus. This discussion includes forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth under "Risk Factors" and elsewhere in this prospectus, our actual results may differ materially from those anticipated in these forward-looking statements. Financial Operations Overview We are a development stage company and have only recently commenced operations and have generated only minimal revenues. During the year ended December 31, 2008 we generated $10,000 of revenue and incurred operating expenses of $439,603. Our principal business activities to date have been the acquisition of the Patent. From our inception to December 31, 2008, we had incurred an accumulated deficit of $680,915 and our stockholders' deficit at December 31, 2008 was $103,648. Our accumulated deficit through December 31, 2008 is primarily attributable to the lack of business activity and product sales. -15- Since inception, we have financed our operations from the sale of common stock and contribution from related parties. If our anticipated sales for the next few months do not meet our expectations, our existing resources will not be sufficient to meet our cash flow requirements for the next few months. Furthermore, if our expenses exceed our anticipations, we will need additional funds to implement our business plan. We will not be able to fully establish our business if we do not have adequate working capital and if we do not have adequate working capital we may need to raise additional funds, whether through a stock offering or otherwise. We will need to raise additional money in order to establish a distribution network for the manufacture a...
Click here to read the whole Article (external link)

ImmunoBiotics Presented At the National Investment Banking Association Conference

SAN CLEMENTE, Calif., Dec. 4, 2008 (GLOBE NEWSWIRE) -- ImmunoBiotics, Inc. (OTC BB:IMBI.OB - News), a nutraceutical company focused on the discovery and development of safe and effective natural products in the areas of autoimmune, neurological, and metabolic disorders, announced that Thomas P. Lahey, Chairman and CEO of ImmunoBiotics, presented an overview of the Company at the National Investment Banking Association (http://www.nibanet.org) Capital Conference at 10:25 AM PST on December 4, 2008. The event was held at the Wynn Resort in Las Vegas, Nevada. About ImmunoBiotics, Inc.ImmunoBiotics, Inc., a nutraceutical company focused on the discovery and development of safe and effective treatments for autoimmune, neurological, and metabolic diseases, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of immune activation and neuro-inflammation to design dietary supplements derived from botanical sources which have novel mechanisms of action. Based on the results of early-stage clinical trials, ImmunoBiotics believes they have discovered new classes of drug candidates with the potential to be leaders in their markets. ImmunoBiotics is headquartered in San Clemente, California and is traded on the OTC Bulletin Board under the symbol ``IMBI.'' For mor...
Click here to read the whole Article (external link)

IMMUNOBIOTICS INC Files SEC form 10-Q, Quarterly Report

Item 2. Management's Discussion and Analysis of Plan of Operations This discussion and analysis should be read in conjunction with the accompanying Financial Statements and related notes. Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of any contingent liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. On an on-going basis we review our estimates and assumptions. Our estimates are based on our historical experience and other assumptions that we believe to be reasonable under the circumstances. Actual results are likely to differ from those estimates under different assumptions or conditions, but we do not believe such differences will materially affect our financial position or results of operations. Our critical accounting policies, the policies we believe are most important to the presentation of our financial statements and require the most difficult, subjective and complex judgments, are outlined below in ''Critical Accounting Policies,'' and have not changed significantly. FORWARD-LOOKING STATEMENTS Certain statements made in this report may constitute "forward-looking statements on our current expectations and projections about future events ". These forward-looking statements involve known or unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the Registrant to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases you...
Click here to read the whole Article (external link)